Effect of mucosal and systemic immunization with virus‐like particles of severe acute respiratory syndrome coronavirus in mice

Immunology - Tập 130 Số 2 - Trang 254-261 - 2010
Baojing Lu1,2, Yi Huang2, Li Huang2, Li Bao1, Zhenhua Zheng2, Ze Chen2, Jianjun Chen2, Qinxue Hu2, Sheng Wang2
1Anhui Medical University, Hefei, China
2State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Science, Wuhan

Tóm tắt

SummaryNasal administration has emerged as a promising and attractive route for vaccination, especially for the prophylaxis of respiratory diseases. Our previous studies have shown that severe acute respiratory syndrome coronavirus (SARS‐CoV) virus‐like particles (VLPs) can be assembled using a recombinant baculovirus (rBV) expression system and such VLPs induce specific humoral and cellular immune responses in mice after subcutaneous injection. Here, we investigated mucosal immune responses to SARS‐CoV VLPs in a mouse model. Mice were immunized in parallel, intraperitoneally or intranasally, with VLPs alone or with VLPs plus cytosine–phosphate–guanosine (CpG). Immune responses, including the production of SARS‐CoV‐specific serum immunoglobulin G (IgG) and secretory immunoglobulin A (sIgA), were determined in mucosal secretions and tissues. Both immunizations induced SARS‐CoV‐specific IgG, although the levels of IgG in groups immunized via the intraperitoneal (i.p.) route were higher. sIgA was detected in saliva in groups immunized intranasally but not in groups immunized intraperitoneally. CpG had an adjuvant effect on IgA production in genital tract washes when administered intranasally but only affected IgA production in faeces samples when administered intraperitoneally. In addition, IgA was also detected in mucosal tissues from the lung and intestine, while CpG induced an increased level of IgA in the intestine. Most importantly, neutralization antibodies were detected in sera after i.p. and intranasal (i.n.) immunizations. Secretions in genital tract washes from the i.n. group also showed neutralization activity. Furthermore, VLPs that were administered intraperitoneally elicited cellular immune responses as demonstrated by enzyme‐linked immunospot (ELISPOT) assay analyses. In summary, our study indicates that mucosal immunization with rBV SARS‐CoV VLPs represent an effective means for eliciting protective systemic and mucosal immune responses against SARS‐CoV, providing important information for vaccine design.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa030747

10.1016/S0140-6736(03)13077-2

10.1126/science.1085953

10.1126/science.1085952

10.1002/pmic.200300676

10.1126/science.1068284

10.1016/j.ymeth.2006.07.018

10.1073/pnas.082281199

10.1016/0092-8674(89)90873-8

10.1016/j.jbiotec.2005.03.026

10.1016/S0264-410X(03)00308-6

10.1128/JVI.78.13.6995-7003.2004

10.1073/pnas.1131929100

10.1016/j.virol.2009.04.004

10.1128/JVI.72.10.8220-8229.1998

10.1016/j.vaccine.2009.02.029

10.1016/j.vaccine.2008.06.002

10.1016/j.bbrc.2004.04.111

10.1016/j.febslet.2004.09.009

10.1371/journal.pone.0002685

10.1111/j.1365-2567.2007.02676.x

10.1073/pnas.94.10.5267

10.1128/JVI.77.6.3615-3623.2003

Davis HL, 1998, CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen 1, J Immunol, 160, 870, 10.4049/jimmunol.160.2.870

10.1074/jbc.M500662200

10.1128/JVI.79.18.11638-11646.2005

10.1038/nature02463

10.1016/j.ymthe.2004.06.485

10.1128/JVI.79.22.13915-13923.2005

10.1016/j.vaccine.2005.08.055

10.1128/CVI.00019-07

10.1016/S0171-2985(11)80473-0

McCluskie MJ, 1998, CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice, J Immunol, 161, 4463, 10.4049/jimmunol.161.9.4463

10.1006/cimm.1998.1400

10.1016/S0264-410X(98)80122-9

10.1002/eji.200636959

10.1007/s00705-004-0447-z

10.1089/vim.2007.0079

10.4049/jimmunol.166.5.3451

10.1038/374546a0

Thông tin
Thông tin xuất bản

Immunology

Tập 130 Số 2

254-261

Thông tin tác giả